Each month the eanNews editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for June 2025.
Category
EAN News
Here you will find news from the EAN as well as updates on their activities.
-
-
EAN NewsResident and Research Fellows
Transformative year will “reshape our section of the society” says former RRFS Chair
June 4, 2025Former EAN Residents & Research Fellows Section Chair, Giacomo Sferruzza looks back on a year of transformative events for the rapidly growing community. -
EAN News
Keeping the past for the future – long serving archivists step down and welcome a new EAN historian
June 4, 2025When the EAN was founded in 2014, the 1st EAN President Günther Deuschl decided that we should have an EAN archive. He invited two members of the mother societies ENS and EFNS to volunteer as “historians” and become the first… Continue Reading -
Executive PageEAN NewsEAN Congress newsFeatured Slider
Executive Page: Get ready for EAN 2025 in Helsinki!
June 3, 2025EAN Programme Committee Chair, Irena Rektorová, & EAN President, Elena Moro preview some major highlights of the EAN Congress 2025, taking place in Helsinki in just a few weeks. -
Welcome to the June 2025 edition of the President’s Corner, our article series in which the EAN President, Elena Moro, answers your questions!
-
Paper of the MonthEAN NewsFeatured Slider
Research Papers of the Month: Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease / Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease
June 2, 2025Our papers of the month for June are two studies that suggest that transplantation of dopaminergic progenitor cells into the striatum may confer meaningful clinical benefits for patients with Parkinson’s disease. -
Each month the eanNews editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for May 2025.
-
Brain HealthEAN NewsEAN Congress news
Public Brain Health Day at the EAN Congress 2025 in Helsinki
May 8, 2025Together with the Brain Health Mission, the EAN is excited to announce the launch of the Public Brain Health Day, on Monday, 23 June 2025, during the 11th EAN Congress in Helsinki. -
Brain HealthEAN News
9th ESF Sleep Medicine School offers creative insights into sleep and brain health
May 8, 2025The University of Cyprus in Nicosia was thrilled to host the highly anticipated 9th European Sleep Foundation (ESF) Sleep Medicine School from 31 March to 3 April 2025, endorsed by the EAN. -
Executive PageEAN NewsFeatured Slider
Executive Page: panels, guidelines, EBRAINS, and more ways to get involved in EAN scientific activities
May 7, 2025EAN Scientific Committee Chair, Gereon R. Fink, provides a look at various ongoing projects, including a variety of ways you can contribute to EAN scientific activities. -
Welcome to the May 2025 edition of the President’s Corner, our article series in which the EAN President, Elena Moro, answers your questions!
-
Paper of the MonthEAN NewsFeatured Slider
Research Papers of the Month: Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis / Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis
May 7, 2025Our papers of the month for May are two papers present findings from recent trials evaluating the efficacy and safety of tolebrutinib in patients with multiple sclerosis. -
AdvocacyResearch FundingEAN NewsScientific CornerTop Articles
Draft Innovative Health Initiative (IHI) Funding Call topics related to the brain
May 2, 2025The Innovative Health Initiative (IHI) has just published draft topic texts for its upcoming Call 11, expected to launch officially in late June 2025. -
The EAN was asked by a media outlet to provide comment on the possible role of creatine in the prevention of Alzheimer’s disease, the subject of much recent internet speculation.
-
EAN NewsResearch
EU Commission approves Leqembi (Lecanemab) for treatment of early-stage Alzheimer’s disease
April 17, 2025Following an earlier decision by the EMA, the EU Commission has granted EU authorisation for Lecanemab to treat mild cognitive impairment in the early stages of Alzheimer’s disease.
Newer Posts